Document is current

Article History

Received: 23 October 2024

Accepted: 4 January 2025

First Online: 10 February 2025

Declarations

:

: The study was funded by Novartis Pharma GmbH. The authors had complete autonomy for the process of designing the study, carrying out the analyses, interpreting the results, and preparing the manuscript. This also includes the full right to publish the results without limitation. KCM and AH are employees of the IGES Institut GmbH, which is a paid consultant to Novartis Pharma GmbH for conducting the study and preparing the manuscript. At the time of this study, VW and AM were employees of the IGES Institut GmbH. BM and RN are employees of the InGef – Institute for Applied Health Research Berlin GmbH, which was contracted and reimbursed by IGES Institut GmbH for providing the data and carrying out the analyses.KM, MF, and SG are employees of Novartis Pharma GmbH.FA received consulting fees from Abbott, Almirall, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, InGef, Lundbeck, Novartis, NovoNordisk, Shire, and Xcenda.HKA received research support from Bristol-Myers Squibb, Incyte, and Novartis, consulting fees from AbbVie, AOP Health, Bristol-Myers Squibb, GSK, Novartis, and Otsuka, advisory board fees from AbbVie, AOP Health, Blueprint, Bristol-Myers Squibb, GSK, and Novartis, and a travel grant from Alexion.

: Since all patient-level data in the database are anonymized to comply with German data protections regulations and German federal law, approval of an Ethics Committee was not required. The research was conducted in accordance with the Declaration of Helsinki.

: Since anonymized administrative claims data were used and presented only in aggregate form, informed consent of patients was not required. The pre-existing database did not allow direct identification of patients, and no contact was made with patients.